Evidence map›Paper›PMID 27817866›Full record

ArticleAmerican journal of human genetics2016

HLA-C Level Is Regulated by a Polymorphic Oct1 Binding Site in the HLA-C Promoter Region.

Nicolas Vince, Hongchuan Li, Veron Ramsuran, Vivek Naranbhai, Fuh-Mei Duh, Benjamin P Fairfax, Bahara Saleh, Julian C Knight, Stephen K Anderson, Mary Carrington

Open access · bronzeAbstract read
In one paragraph

Article in American journal of human genetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.7field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 61 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. HLA Alleles BFrontiers in immunology · 2021
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Nicolas VinceCancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Hongchuan LiCancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Veron RamsuranCancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Vivek NaranbhaiRagon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA; Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK; Center for the AIDS Programme of Research in South Africa, University of KwaZuluNatal, Durban 4091, South Africa.
Fuh-Mei DuhCancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Benjamin P FairfaxWellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
Bahara SalehCancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Julian C KnightWellcome Trust Centre for Human Genetics, University of Oxford, Oxford OX3 7BN, UK.
Stephen K AndersonCancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA.
Mary CarringtonCancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA. Electronic address: carringm@mail.nih.gov.
Leidos (United States) · USFrederick National Laboratory for Cancer Research · USUniversity of Oxford · GB

Funding

Molecular genetics and population studies of the KIR and HLA gene complexesZIABC010792 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI CARRINGTON, MARY N. · 2009 to 2025
$7.8M
CCR NIH HHS HHSN261200800001CEuropean Research Council 281824Medical Research Council G1001708NCI NIH HHS HHSN261200800001EWellcome Trust 074318Wellcome Trust 088891
6 · The paper itself

Abstract

Differential HLA-C levels influence several human diseases, but the mechanisms responsible are incompletely characterized. Using a validated prediction algorithm, we imputed HLA-C cell surface levels in 228 individuals from the 1000 Genomes dataset. We tested 68,726 SNPs within the MHC for association with HLA-C level. The HLA-C promoter region variant, rs2395471, 800 bp upstream of the transcription start site, gave the most significant association with HLA-C levels (p = 4.2 × 10

Indexed as

AlgorithmsAllelesBinding SitesDatasets as TopicGenome, HumanGenome-Wide Association StudyHeLa CellsHLA-C AntigensHumansOctamer Transcription Factor-1Polymorphism, Single NucleotidePromoter Regions, GeneticQuantitative Trait LociTranscription, GeneticTranscription Initiation SiteHLA-C AntigensOctamer Transcription Factor-1

Identifiers

PMID27817866
PMCPMC5142108
OpenAlexW2546442416

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.